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In an era in which science and medicine
make front-page news in the lay press, it
is critical that the complex workings of
clinical investigation be portrayed accu-
rately to the public. The appetite for news
of medical “breakthroughs” seems insa-
tiable at times. In this setting, sensational
articles about medicine, physicians, and
pharmaceutical companies can easily find
an attentive audience that may be unable
to distinguish truth from sensationalism.
To provide a case study for how inaccurate
and dangerous the mainstream press can
be if articles are not carefully written, as
well as to correct inaccuracies and defend
honesty in research, we offer our coun-
terpoint to a recent article [1] that ques-
tions the various systems of checks and
balances that govern the conduct of clin-
ical trials and implicitly accuses one of our
infectious diseases colleagues of unethical
conduct in 2 clinical trials.
In “A Times Investigation: Drug Trials
with a Dose of Doubt” [1], an article writ-
ten by reporter David Willman and pub-
lished in the Los Angeles Times, Dr.
Thomas Walsh, the Chief of the Immu-
nocompromised Host Section, Pediatric
Oncology Branch, National Cancer Insti-
tute, National Institutes of Health (NIH),
was implicitly accused of unethical con-
duct in 2 randomized, controlled trials of
empirical antifungal therapy for persistent
neutropenic fever. Walsh was the lead au-
thor of both of these multicenter trials,
both of which were published in the New
England Journal of Medicine [2, 3]. The
first study compared conventional deox-
ycholate amphotericin B (D-AmB) with
liposomal amphotericin B (L-AmB), and
the second compared L-AmB with cas-
pofungin. Specifically, Walsh, the principal
investigator, was implicitly accused of de-
liberately underdosing the standard ther-
apy drug to favor the investigational agent
of the pharmaceutical sponsor.
We use the term “implicitly accused,”
because Willman is careful to not make
explicit accusations of wrongdoing. How-
ever, when all of the misleading state-
ments, nonsequiturs, loaded and pejora-
tive descriptions, and selected quotations
are strung together, Willman creates the
image of a respected NIH scientist and
pharmaceutical companies colluding to
rig trials to win US Food and Drug Ad-
ministration (FDA) approval for the fa-
vored drug (table 1). Willman implies that
the biased trial design jeopardized patient
safety because patients with life-threat-
ening infections were treated with inade-
quate doses of antifungals. Implicit in
these accusations is the contention that
 at K
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experienced physicians at multiple levels
of oversight—including physicians at the
NIH and FDA, site investigators and
members of institutional review boards at
dozens of health care centers, and the
members of the New England Journal of
Medicine editorial boards—either actively
colluded in this conspiracy or had such
poor knowledge about empirical antifun-
gal therapy that they did not realize that
a conspiracy had occurred. Although the
title “Drug Trials with a Dose of Doubt”
is an attention grabber that sells newspa-
pers, an accurate representation of the
facts will show that these trials were con-
ducted with sterling integrity.
JUST GETTING STARTED
Willman opens his “investigation” with
the implicit accusation that Walsh had ex-
traordinary influence over the FDA’s ap-
proval of caspofungin. Caspofungin was
initially approved as therapy for invasive
aspergillosis in patients with refractory in-
fection or intolerance to standard therapy.
Willman correctly notes that the database
involved a limited number of patients.
However, this drug, representing a new
class, was free of serious toxicity and had
encouraging results in treating this life-
threatening infection [5]. The FDA
weighed the limited but supportive data-
base, the acute, unmet need for effective
therapeutics against aspergillosis, and the
recommendations of its 12 independent
advisory board members, and arrived at
the very reasonable decision to approve
caspofungin. Yet, Willman gives the false
impression that Walsh had a singular in-
fluence over the FDA’s decision. “Merck
summoned to the microphone one of its
announced consultants, a man whose gov-
ernment job was nearby, at the NIH. Dr.
Thomas J. Walsh assured the committee
that Merck’s data describing the patients
was ‘extremely robust and very, very
rigorous.’ … The advisory committee
voted unanimously to endorse the drug
… Sixteen days later, the FDA approved
it” [1].
On the basis of Willman’s remarks, an
intelligent lay person may question
whether the FDA actually looked at the
data or whether Walsh’s remarks at the
microphone were all the assurances that
the FDA needed. The absurdity of this sce-
nario is stunning, and yet Willman sup-
ports this allegation with a series of non
sequiturs. Because Walsh and the FDA
physicians are federal employees, Willman
implies that Walsh must be in a unique
position to influence FDA decisions and
to single-handedly attain FDA approval of
major drugs. The NIH and the FDA are
entirely separate federal administrations
with distinct missions and oversight. What
is the evidence for Walsh’s purported ex-
cessive influence over the FDA? None ex-
ists. Unfortunately, Willman was just get-
ting started.
CONSPIRACY BETWEEN WALSH
AND THE PHARMACEUTICAL
INDUSTRY TO RIG THE DRUG-
APPROVAL PROCESS?
At the heart of the Willman “expose´” is
the contention (although it is never ex-
plicitly stated) that the 2 clinical trials were
rigged to increase the likelihood of FDA
approval of the investigational drugs. Will-
man’s evidence consists of selective quo-
tations from letters to the editor that raised
concerns about the dose of standard drug
used in the trials. Willman’s use of these
selective quotations is antithetical to the
rigorous, unbiased science that he claims
to defend. Letters to the editor serve as a
forum for debating points in published
material and are typically critical. Some
letters make cogent arguments. Others do
not. More importantly, letters to the editor
are typically authored by one or a few phy-
sicians, do not reflect broad consensus,
and, unlike the article that they critique,
are not subject to rigorous peer review.
The web of deceit that is implicitly alleged
in this conspiracy theory is intricate but
centers on 2 issues: selective enrollment of
patients and picking dosages of antifungals
to bias outcome.
PICKING PATIENTS
The first layer of purported deceit implic-
itly alleged by Willman’s article [1] in-
volved the selection of the type of trial that
would have the highest likelihood of se-
curing FDA approval. Willman states that,
“for makers of new antifungal drugs, less
burdensome clinical study standards could
make it easier to get the products
approved … for instance some companies
wanted to enroll cancer patients with sus-
pected but unproven fungal infections,”
thereby implying that studies of empirical
therapy are not scientifically valid and are
only designed for cherry-picked patients.
We disagree. The rationale for empirical
therapy is to treat a potential occult in-
vasive fungal infection before it becomes
clinically overt. This concept is based on
the central tenet that early treatment of
invasive fungal infections improves out-
come and that lower doses, when used
early, may benefit patients—particularly
those patients with infections that are dif-
ficult to diagnose (such as invasive fungal
infections). Before the development of
empirical therapy, unsuspected infections
with Candida species, Aspergillus species,
and other fungi were frequently diagnosed
at autopsy [6, 7]. Empirical antifungal
therapy, as conducted in the 2 trials at
issue, has been studied in 13000 patients
and has been endorsed in authoritative
guidelines from infectious diseases and he-
matology professional societies in North
America and Europe [8, 9]. At the time
that the 2 trials in question were designed,
empirical antifungal therapy was a bed-
rock principle and standard-of-care for
patients at risk for suspected fungal infec-
tions and was, therefore, a legitimate sub-
ject of clinical investigation. The recent
availability of safe antifungal agents and
improved diagnostic tools has opened a
scientific debate about the current role of
empirical therapy, with some investigators
advocating different approaches [10].
These and other differences of opinion
represent the scientific debate that is part
and parcel of any scientific field.
 at K
atholieke U
niversiteit on July 10, 2012
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AND PICKING DOSES
The second and more serious of Willman’s
implicit accusations is that Walsh delib-
erately chose to administer lower, less-ef-
fective dosages of comparator drugs in the
2 trials. In trial 1, D-AmB (0.6 mg/kg per
day) was compared with L-AmB (3 mg/
kg per day). In trial 2, L-AmB (3 mg/kg
per day) was compared with caspofungin
(70 mg administered once, followed by a
regimen of 50 mg per day). Willman [1]
implicitly alleges that D-AmB (the control
drug) was underdosed in trial 1. He fur-
ther suggests that, in trial 2, it was L-AmB
(now the control drug), that was under-
dosed to favor caspofungin. That the dose
of L-AmB was the same in both trials
makes these allegations self-contradictory
and logically untenable.
In fact, the dosages of all drugs used in
both trials were appropriate on the basis
of substantial published data. Consensus
supporting the 0.6 mg/kg per day D-AmB
dosage in trial 1 [2] and the 3 mg/kg per
day L-AmB dosage in trial 2 [3] is based
on the following data. First, D-AmB was
administered at a dosage of 0.5–0.6 mg/
kg per day in prior studies of empirical
therapy that established the safety of this
approach and suggested a protective ben-
efit [6, 11].
Second, no evidence of superior out-
comes associated with higher dosages of
D-AmB or L-AmB has ever been pub-
lished. In a randomized, controlled trial
of empirical therapy that compared D-
AmB 1 mg/kg per day versus L-AmB 1
mg/kg per day versus L-AmB 3 mg/kg per
day, D-AmB recipients had a response rate
comparable to that of patients treated with
L-AmB, but they experienced greater ne-
phrotoxicity (23%) than did patients re-
ceiving L-AmB 1 mg/kg per day (0%) or
L-AmB 3 mg/kg per day (3%) ( )Pp .01
[12]. These results were similar to those
for trial 1 (D-AmB vs. L-AmB) [2], which
showed comparable efficacy but higher
nephrotoxicity in the D-AmB 0.6 mg/kg
per day group than in the L-AmB 3 mg/
kg per day group. In another study of em-
pirical antifungal therapy, L-AmB admin-
istered at a dosage of 3 mg/kg per day and
5 mg/kg per day had similar efficacy and
toxicity [13]. Finally, a recent trial of pri-
mary therapy for invasive aspergillosis (the
AmBiLoad study [4]) showed that L-AmB
(3 mg/kg per day, which is the same dosage
that was administered in the empirical tri-
als) was equally effective but less toxic than
a 10 mg/kg per day regimen of L-AmB.
Yet, Willman [1] creates the misleading
impression that patients enrolled in these
empirical trials may have died of break-
through aspergillosis because of inade-
quate dosing of D-AmB or L-AmB. The
results discussed above, particularly the
findings of the AmBiLoad study, dispel the
false notion that administering higher dos-
ages of drug is equated with improved ef-
ficacy, and they unequivocally give further
validation of the dosages used in the Walsh
trials in question [2, 3].
Third, there is evidence of increasing
dose-dependent toxicity with D-AmB.
Even a superficial review of the literature
would find multiple reports of high rates
of dose-limiting nephrotoxicity associated
with D-AmB use [4, 12, 14–18]. D-AmB–
related nephrotoxicity has been shown to
be an independent risk factor for mortality
[14]. Yet, Willman [1] chose to ignore
these well-documented, substantial pa-
tient safety concerns in his discussion of
the D-AmB versus L-AmB empirical trial.
PATIENT SAFETY WAS
OF PRIMARY IMPORTANCE
The majority of patients who receive em-
pirical antifungal therapy do not have an
occult fungal infection. Therefore, this ap-
proach necessarily entails treating many
individuals to benefit a minority of pa-
tients. It is, therefore, of key importance
that the regimen be safe. Willman’s con-
tention that patients were put at risk by
unethical trial design flies in the face of
his article’s [1] total disregard of the in-
herent toxicities in AmB-based antifungal
therapy mentioned above [4, 12, 14–16,
18]. Furthermore, the dosages of D-AmB
and L-AmB in trial 1 [2] were agreed upon
by all 32 investigators and by senior mem-
bers and statisticians of the Mycoses Study
Group and were approved by participating
health care center institutional review
boards, the National Institute of Allergy
and Infectious Disease protocol review
committee, and the FDA. Patient safety
measures were stringent and relied on
baseline evaluation to exclude invasive
fungal infection, included monitoring for
breakthrough invasive fungal infection
during therapy, allowed for dosage mod-
ification (with dosage to be increased if
invasive fungal infection was suspected
and decreased in response to toxicity), and
included prospective data review by an in-
dependent data safety monitoring board.
D-AmB recipients had significantly more
frequent dose reductions because of tox-
icity than did L-AmB recipients. This find-
ing totally discredits the theory of delib-
erate underdosing of D-AmB. Further, the
difference in the number of deaths asso-
ciated with each therapy, emphasized in
Willman’s article [1], was, in fact, not sta-
tistically significant in this cohort of 687
patients [2].
Willman [1] further suggests a disregard
for patient safety by claiming that the L-
AmB dosage in the L-AmB versus cas-
pofungin trial [3] could not be increased
until a patient had received 5 days of the
original dosage of investigational or com-
parator drugs and continued to deterio-
rate. The implication is that the patient’s
life and health were endangered by re-
maining on ineffective treatment until the
5-day limit. However, Willman acknowl-
edges that “A patient also could be re-
moved from the study and treated differ-
ently” and that “the five-day provision
… was intended to standardize the con-
ditions for increasing the dosages” and
“was approved by all investigators, their
institutional review boards, and the FDA”
[1]. That is, the study design encouraged
investigators to act as doctors and to err
on the side of patient safety, even if doing
so meant removing a patient from the
trial, because patient safety was at the heart
of the investigators’ concerns.
The implied accusation that the L-AmB
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dosage was suboptimal in trial 2 [3] (but
not in trial 1, which used the same dosage
[2]) is inconsistent with overwhelming
evidence indicating that the 3 mg/kg per
day L-AmB dosage is justified for empir-
ical therapy. The implicit accusation also
demonstrates a lack of knowledge of reg-
ulatory oversight. On the basis of the re-
sults of trial 1 [2], L-AmB was approved
by the FDA as empirical therapy for neu-
tropenic fever at a dosage of 3 mg/kg per
day. The FDA requires the use of standard-
therapy control subjects when investigat-
ing new agents, such as caspofungin.
Therefore, the use of L-AmB at 3 mg/kg
per day in trial 2 was logical, evidence-
based, and required for regulatory
approval.
MULTICENTER TRIALS
REQUIRE BROAD CONSENSUS
AND OVERSIGHT, NOT
A SINGLE VOICE
Although Walsh was an active participant
in discussions to determine dosage selec-
tion (and rightfully so), a consensus by a
large group of expert investigators who
had to approve the study design and nu-
merous layers of regulatory approval were
essential to implement the study. Indeed,
a major element in the success of the
American system of drug approval has
been the system of checks and balances.
These same concepts—plus skilled over-
sight by investigators, regulatory agencies,
and institutional review boards—are an
integral part of our approach to clinical
research, providing expert council for all
aspects of the drug development process.
As imperfect as it might be, this model
remains the gold standard for drug
development.
HAVE ALL SYSTEMS
OF INDEPENDENT OVERSIGHT
BEEN CORRUPTED?
Willman [1] alleges, in effect, that dozens
of investigators worldwide and regulatory
entities conspired actively with Walsh to
harm patients (including causing patient
deaths) or were unaware that a conspiracy
was plotted. If this is true, then the entire
system of oversight of medical research in
the United States and abroad is tainted or
defective.
In addition, although he does not ex-
plicitly say so, Willman [1], in effect, im-
plicitly attacks the NIH (for collaborating
with the pharmaceutical industry and for
incompetent oversight); the competence
and/or integrity of dozens of investigators,
senior Mycoses Study Group members,
and FDA officers (for allowing patient en-
rollment in unethical trials with substan-
dard care); the institutional review boards
at numerous academic institutions (for
uncritically reviewing the study protocols);
the editorial board at the New England
Journal of Medicine (for accepting
publications of unethical research); and
the FDA and its 12-member advisory
board (for approving drugs on the basis
of tainted trials). Indeed, all of these sys-
tems of independent oversight needed to
have failed for the proposed conspiracy
between Walsh and the pharmaceutical in-
dustry to be successful.
We also emphasize Willman’s citation
of Walsh’s superiors: “There is no rational
motivation for an investigator or spon-
soring company to design a trial with a
control arm that is not standard of care”
[1]. We go one step further. We believe it
is impossible to conduct a study involving
dozens of health care centers worldwide if
the control arm does not adhere to a gen-
eral consensus of what is considered to be
standard of care.
CAN PRINCIPAL
INVESTIGATORS PROVIDE
ADVICE TO BOTH
THE PHARMACEUTICAL
INDUSTRY AND THE FDA?
Willman [1] further attacks Walsh on the
inappropriateness of his advice to regu-
latory agencies. In doing so, Willman dis-
regards the major responsibility of prin-
cipal investigators and the data review
committee chair (in collaboration with
other investigators) for study develop-
ment, execution, and analysis, as well as
for presenting results to the relevant agen-
cies. It is entirely appropriate for a prin-
cipal investigator and data review com-
mittee chair to provide advice to both the
pharmaceutical industry and the FDA,
particularly when he happens to be, like
Walsh, an accomplished investigator with
almost 600 peer-reviewed scientific
publications and service on numerous sci-
entific advisory boards. Being a federal
employee does not disqualify Walsh from
providing such advice; he is as qualified
to do so as any other academic investigator
with similar expertise. There is, indeed, a
very small pool of highly qualified indi-
viduals who can deliver such necessary ex-
pertise to both the pharmaceutical indus-
try and the FDA. Such expertise is critical
to the vital scientific collaboration between
the pharmaceutical industry and the sci-
entific community, especially in this time
of decreased federal funding. In fact, all
drugs are brought to market through col-
laboration between the pharmaceutical in-
dustry, independent researchers (includ-
ing some whose research is federally
funded), and the FDA. The 2-decade–long
collaborative federal and pharmaceutical
industry support of the Mycoses Study
Group is but one example of positive in-
teraction that had led to major develop-
ments in antifungal therapy.
A HUGE DOSE OF DOUBT
ABOUT THE LOS ANGELES
TIMES
Newspapers owe their readership a mod-
icum of objectivity. This does not equate
with simply presenting both sides of an
argument. It must also give some sense of
the weight of the evidence supporting op-
posing positions, to give some context to
readers and to enable them to reach con-
sidered judgments. Newspaper editors
owe it to their readership to perform a
thorough review of any proposed article
for the validity of the evidence presented
and the reliability of the article’s sources.
The Los Angeles Times has failed its read-
ership on all counts. The destructive na-
ture of Willman’s implicit allegations and
 at K
atholieke U
niversiteit on July 10, 2012
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
1036 • CID 2006:43 (15 October) • Anaissie et al.
the strong rebuttals made by several in-
vestigators and by Walsh’s superiors sev-
eral months before the publication of
Willman’s article [1] should have
prompted Willman’s editors to scrutinize
carefully the quality of his “evidence.”
Their failure to do so calls into question
the credibility of the Los Angeles Times as
a serious newspaper. Accordingly, the ed-
itors bear responsibility, together with
Willman, for this publication. One might
ask at what point reporters and editors
cross the line of ethical reporting. If any-
thing, this sad chapter should give the
public a huge dose of doubt about this
newspaper.
The core of Willman’s implied accu-
sations against Walsh—that dosages of an-
tifungals were manipulated to bias the 2
empirical trials in favor of the investiga-
tional agents—has been discredited in the
preceding discussion. But another dis-
turbing fact is the lack of objectivity dis-
played during the conduct of the “inves-
tigations” that led to the inaccurate article
[1]. Willman began his “investigations” of
Walsh in mid-2005 with several accusa-
tions (Thomas Walsh, personal corre-
spondence). Eight of us rebutted Will-
man’s accusations in a detailed,
point-by-point response in November
2005. This response did not satisfy Will-
man, but prompted him to write another
letter in February 2006, which contained
even more queries. An extensive response
was provided to Willman and his editors
in June 2006 that further detailed the gross
misrepresentations of his implied allega-
tions. This, too, was willfully ignored, and
Willman’s article [1] was published in July
2006. Our criticisms of Willman’s flawed
assertions are acknowledged in passing in
his article, by statements such as “much
controversy still surrounds the optimal
timing, dosage and duration of therapy for
patients with suspected infections”; “no
published study has established that a
higher dose of an antifungal drug is more
effective in treating suspected infection
and that some studies have suggested that
lower dosing may provide similar bene-
fits”; “drug dosages were not chosen by
Walsh individually but with assent of other
researchers”; and, “study designs were re-
viewed and approved by the FDA and in-
stitutional review boards of participating
centers” [1]. One would think that these
statements, in and of themselves, would
exonerate Walsh of culpability with respect
to the core accusations. However, un-
daunted by the above-mentioned facts,
Willman relies on far less authoritative
sources, such as “some investigators“ (un-
named) and selective quotations from the
correspondence sections of medical jour-
nals, to support the implicit allegations of
conspiracy.
POTENTIAL IMPLICATIONS
OF WILLMAN’S ARTICLE
Sensational attacks on a respected aca-
demic and government employee (and,
implicitly, on the entire drug-approval
process) and fear-mongering addressed to
the lay reader (implying that individuals
should enroll in clinical trials at their own
risk) may be attention-grabbing ways to
sell more newspapers; for this purpose,
Walsh served as a convenient scapegoat.
As colleagues of Dr. Walsh, we are deeply
concerned that his reputation is being un-
fairly maligned. To his patients and col-
leagues, Dr. Walsh is a compassionate phy-
sician whose dedication to the care of
immunocompromised children and
adults is central to his professional life. To
his colleagues worldwide, Dr. Walsh is an
outstanding investigator who has substan-
tively advanced the field of antifungal
therapy. This is the real story of Dr. Walsh.
The greatest danger of articles such as
Willman’s [1] is that members of the lay
public do not read medical journals. By
contrast, the Los Angeles Times is widely
read, is disseminated online, and is per-
ceived as an authoritative news source. Ac-
cordingly, there is good reason to fear that
the public will conclude, on the basis of
Willman’s article [1], that the entire pro-
cess of drug development in the United
States and abroad is corrupt and that they
should refrain from participating in clin-
ical trials. We question whether Willman
and the Los Angeles Times considered the
possibility that future patients might suffer
as a result of Willman’s irresponsible
report.
As clinical researchers who require the
trust of the public, we expect and welcome
scrutiny by the lay press. But we also have
the responsibility to vigorously defend our
colleagues when their professional integ-
rity has been unfairly maligned and to re-
store public confidence in clinical research
and its systems of independent oversight
when they have been unfairly attacked.
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